Low expression of MEOX2 is associated with poor survival in patients with breast cancer
To investigate associations of MEOX2 expression with clinicopathological features and survival of breast cancer patients. We used a breast cancer tissue microarray for immunohistochemistry. Associations between MEOX2 expression and clinicopathological features were analyzed using the χ-square test....
Gespeichert in:
| Veröffentlicht in: | Biomarkers in medicine 2022-11, Vol.16 (16), p.1161-1170 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1170 |
|---|---|
| container_issue | 16 |
| container_start_page | 1161 |
| container_title | Biomarkers in medicine |
| container_volume | 16 |
| creator | Wang, Huxia Tang, Yanan Wang, Meixia Zhao, Jing Ding, Caixia Yang, Xiaomin Han, Pihua Liu, Peijun |
| description | To investigate associations of MEOX2 expression with clinicopathological features and survival of breast cancer patients.
We used a breast cancer tissue microarray for immunohistochemistry. Associations between MEOX2 expression and clinicopathological features were analyzed using the χ-square test. Survival analysis was determined using a Kaplan–Meier curve. Multivariate Cox regression was used to determine associations of MEOX2 expression with overall survival.
We found that 74.1% of patients (100/135) had expression of MEOX2 at varying levels. MEOX2 was associated with histological grade and negatively correlated with Ki67 expression. Lower MEOX2 expression was significantly associated with decreased overall survival (p = 0.0011).
MEOX2 expression could be a novel diagnostic and prognostic biomarker of breast cancer.
In this study we found that lower expression of the protein MEOX2 was associated with poor overall survival in breast cancer. MEOX2 is an independent prognostic factor for breast cancer patients. It would be a new diagnostic and prognostic biomarker for breast cancer. |
| doi_str_mv | 10.2217/bmm-2022-0468 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2763334634</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2763334634</sourcerecordid><originalsourceid>FETCH-LOGICAL-c299t-2dc23bb42e7037336d0a17118146e413e00b63be61b9f29062f9f6ba29bc42303</originalsourceid><addsrcrecordid>eNp1kD1PwzAQhi0EgvIxsiKPLAH7nDrNiCq-pKIuINgs27kIoyYOdkLh3-MqpRvT3emee3V6CDnn7AqAF9emaTJgABnL5WyPTHgxTb0o-P6ul-KIHMf4wdi0KCQckiMhJUxhOpuQ14VfU_zuAsbofEt9TZ9ul29AXaQ6Rm-d7rGia9e_0877QOMQvtyXXlHX0k73Dts-jmsTUMeeWt1aDKfkoNariGfbekJe7m6f5w_ZYnn_OL9ZZBbKss-gsiCMyQGL9LMQsmKaF5zPeC4x5wIZM1IYlNyUNZRMQl3W0mgojc1BMHFCLsfcLvjPAWOvGhctrla6RT9EBYUUQuRS5AnNRtQGH2PAWnXBNTr8KM7UxqVKLtXGpdq4TPzFNnowDVY7-k9eAsoRqId-SAJtkmFRjVO6cNa1-E_4L-frgjo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2763334634</pqid></control><display><type>article</type><title>Low expression of MEOX2 is associated with poor survival in patients with breast cancer</title><source>MEDLINE</source><source>PubMed Central</source><creator>Wang, Huxia ; Tang, Yanan ; Wang, Meixia ; Zhao, Jing ; Ding, Caixia ; Yang, Xiaomin ; Han, Pihua ; Liu, Peijun</creator><creatorcontrib>Wang, Huxia ; Tang, Yanan ; Wang, Meixia ; Zhao, Jing ; Ding, Caixia ; Yang, Xiaomin ; Han, Pihua ; Liu, Peijun</creatorcontrib><description>To investigate associations of MEOX2 expression with clinicopathological features and survival of breast cancer patients.
We used a breast cancer tissue microarray for immunohistochemistry. Associations between MEOX2 expression and clinicopathological features were analyzed using the χ-square test. Survival analysis was determined using a Kaplan–Meier curve. Multivariate Cox regression was used to determine associations of MEOX2 expression with overall survival.
We found that 74.1% of patients (100/135) had expression of MEOX2 at varying levels. MEOX2 was associated with histological grade and negatively correlated with Ki67 expression. Lower MEOX2 expression was significantly associated with decreased overall survival (p = 0.0011).
MEOX2 expression could be a novel diagnostic and prognostic biomarker of breast cancer.
In this study we found that lower expression of the protein MEOX2 was associated with poor overall survival in breast cancer. MEOX2 is an independent prognostic factor for breast cancer patients. It would be a new diagnostic and prognostic biomarker for breast cancer.</description><identifier>ISSN: 1752-0363</identifier><identifier>EISSN: 1752-0371</identifier><identifier>DOI: 10.2217/bmm-2022-0468</identifier><identifier>PMID: 36625258</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>biomarker ; Biomarkers, Tumor ; breast cancer ; Breast Neoplasms - metabolism ; clinicopathological features ; diagnosis ; Disease-Free Survival ; Female ; histological grade ; Homeodomain Proteins - genetics ; Humans ; Immunohistochemistry ; Kaplan-Meier Estimate ; Ki67 ; MEOX2 ; overall survival ; Prognosis ; Survival Analysis</subject><ispartof>Biomarkers in medicine, 2022-11, Vol.16 (16), p.1161-1170</ispartof><rights>2023 Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c299t-2dc23bb42e7037336d0a17118146e413e00b63be61b9f29062f9f6ba29bc42303</cites><orcidid>0000-0003-0529-387X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36625258$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Huxia</creatorcontrib><creatorcontrib>Tang, Yanan</creatorcontrib><creatorcontrib>Wang, Meixia</creatorcontrib><creatorcontrib>Zhao, Jing</creatorcontrib><creatorcontrib>Ding, Caixia</creatorcontrib><creatorcontrib>Yang, Xiaomin</creatorcontrib><creatorcontrib>Han, Pihua</creatorcontrib><creatorcontrib>Liu, Peijun</creatorcontrib><title>Low expression of MEOX2 is associated with poor survival in patients with breast cancer</title><title>Biomarkers in medicine</title><addtitle>Biomark Med</addtitle><description>To investigate associations of MEOX2 expression with clinicopathological features and survival of breast cancer patients.
We used a breast cancer tissue microarray for immunohistochemistry. Associations between MEOX2 expression and clinicopathological features were analyzed using the χ-square test. Survival analysis was determined using a Kaplan–Meier curve. Multivariate Cox regression was used to determine associations of MEOX2 expression with overall survival.
We found that 74.1% of patients (100/135) had expression of MEOX2 at varying levels. MEOX2 was associated with histological grade and negatively correlated with Ki67 expression. Lower MEOX2 expression was significantly associated with decreased overall survival (p = 0.0011).
MEOX2 expression could be a novel diagnostic and prognostic biomarker of breast cancer.
In this study we found that lower expression of the protein MEOX2 was associated with poor overall survival in breast cancer. MEOX2 is an independent prognostic factor for breast cancer patients. It would be a new diagnostic and prognostic biomarker for breast cancer.</description><subject>biomarker</subject><subject>Biomarkers, Tumor</subject><subject>breast cancer</subject><subject>Breast Neoplasms - metabolism</subject><subject>clinicopathological features</subject><subject>diagnosis</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>histological grade</subject><subject>Homeodomain Proteins - genetics</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Kaplan-Meier Estimate</subject><subject>Ki67</subject><subject>MEOX2</subject><subject>overall survival</subject><subject>Prognosis</subject><subject>Survival Analysis</subject><issn>1752-0363</issn><issn>1752-0371</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kD1PwzAQhi0EgvIxsiKPLAH7nDrNiCq-pKIuINgs27kIoyYOdkLh3-MqpRvT3emee3V6CDnn7AqAF9emaTJgABnL5WyPTHgxTb0o-P6ul-KIHMf4wdi0KCQckiMhJUxhOpuQ14VfU_zuAsbofEt9TZ9ul29AXaQ6Rm-d7rGia9e_0877QOMQvtyXXlHX0k73Dts-jmsTUMeeWt1aDKfkoNariGfbekJe7m6f5w_ZYnn_OL9ZZBbKss-gsiCMyQGL9LMQsmKaF5zPeC4x5wIZM1IYlNyUNZRMQl3W0mgojc1BMHFCLsfcLvjPAWOvGhctrla6RT9EBYUUQuRS5AnNRtQGH2PAWnXBNTr8KM7UxqVKLtXGpdq4TPzFNnowDVY7-k9eAsoRqId-SAJtkmFRjVO6cNa1-E_4L-frgjo</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Wang, Huxia</creator><creator>Tang, Yanan</creator><creator>Wang, Meixia</creator><creator>Zhao, Jing</creator><creator>Ding, Caixia</creator><creator>Yang, Xiaomin</creator><creator>Han, Pihua</creator><creator>Liu, Peijun</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0529-387X</orcidid></search><sort><creationdate>20221101</creationdate><title>Low expression of MEOX2 is associated with poor survival in patients with breast cancer</title><author>Wang, Huxia ; Tang, Yanan ; Wang, Meixia ; Zhao, Jing ; Ding, Caixia ; Yang, Xiaomin ; Han, Pihua ; Liu, Peijun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c299t-2dc23bb42e7037336d0a17118146e413e00b63be61b9f29062f9f6ba29bc42303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>biomarker</topic><topic>Biomarkers, Tumor</topic><topic>breast cancer</topic><topic>Breast Neoplasms - metabolism</topic><topic>clinicopathological features</topic><topic>diagnosis</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>histological grade</topic><topic>Homeodomain Proteins - genetics</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Kaplan-Meier Estimate</topic><topic>Ki67</topic><topic>MEOX2</topic><topic>overall survival</topic><topic>Prognosis</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Huxia</creatorcontrib><creatorcontrib>Tang, Yanan</creatorcontrib><creatorcontrib>Wang, Meixia</creatorcontrib><creatorcontrib>Zhao, Jing</creatorcontrib><creatorcontrib>Ding, Caixia</creatorcontrib><creatorcontrib>Yang, Xiaomin</creatorcontrib><creatorcontrib>Han, Pihua</creatorcontrib><creatorcontrib>Liu, Peijun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomarkers in medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Huxia</au><au>Tang, Yanan</au><au>Wang, Meixia</au><au>Zhao, Jing</au><au>Ding, Caixia</au><au>Yang, Xiaomin</au><au>Han, Pihua</au><au>Liu, Peijun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low expression of MEOX2 is associated with poor survival in patients with breast cancer</atitle><jtitle>Biomarkers in medicine</jtitle><addtitle>Biomark Med</addtitle><date>2022-11-01</date><risdate>2022</risdate><volume>16</volume><issue>16</issue><spage>1161</spage><epage>1170</epage><pages>1161-1170</pages><issn>1752-0363</issn><eissn>1752-0371</eissn><abstract>To investigate associations of MEOX2 expression with clinicopathological features and survival of breast cancer patients.
We used a breast cancer tissue microarray for immunohistochemistry. Associations between MEOX2 expression and clinicopathological features were analyzed using the χ-square test. Survival analysis was determined using a Kaplan–Meier curve. Multivariate Cox regression was used to determine associations of MEOX2 expression with overall survival.
We found that 74.1% of patients (100/135) had expression of MEOX2 at varying levels. MEOX2 was associated with histological grade and negatively correlated with Ki67 expression. Lower MEOX2 expression was significantly associated with decreased overall survival (p = 0.0011).
MEOX2 expression could be a novel diagnostic and prognostic biomarker of breast cancer.
In this study we found that lower expression of the protein MEOX2 was associated with poor overall survival in breast cancer. MEOX2 is an independent prognostic factor for breast cancer patients. It would be a new diagnostic and prognostic biomarker for breast cancer.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>36625258</pmid><doi>10.2217/bmm-2022-0468</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-0529-387X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1752-0363 |
| ispartof | Biomarkers in medicine, 2022-11, Vol.16 (16), p.1161-1170 |
| issn | 1752-0363 1752-0371 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2763334634 |
| source | MEDLINE; PubMed Central |
| subjects | biomarker Biomarkers, Tumor breast cancer Breast Neoplasms - metabolism clinicopathological features diagnosis Disease-Free Survival Female histological grade Homeodomain Proteins - genetics Humans Immunohistochemistry Kaplan-Meier Estimate Ki67 MEOX2 overall survival Prognosis Survival Analysis |
| title | Low expression of MEOX2 is associated with poor survival in patients with breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T09%3A27%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low%20expression%20of%20MEOX2%20is%20associated%20with%20poor%20survival%20in%20patients%20with%20breast%20cancer&rft.jtitle=Biomarkers%20in%20medicine&rft.au=Wang,%20Huxia&rft.date=2022-11-01&rft.volume=16&rft.issue=16&rft.spage=1161&rft.epage=1170&rft.pages=1161-1170&rft.issn=1752-0363&rft.eissn=1752-0371&rft_id=info:doi/10.2217/bmm-2022-0468&rft_dat=%3Cproquest_cross%3E2763334634%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2763334634&rft_id=info:pmid/36625258&rfr_iscdi=true |